Zobrazeno 1 - 10
of 27
pro vyhledávání: '"David Ladkani"'
Autor:
Fadi Towfic, Jason M Funt, Kevin D Fowler, Shlomo Bakshi, Eran Blaugrund, Maxim N Artyomov, Michael R Hayden, David Ladkani, Rivka Schwartz, Benjamin Zeskind
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e83757 (2014)
For decades, policies regarding generic medicines have sought to provide patients with economical access to safe and effective drugs, while encouraging the development of new therapies. This balance is becoming more challenging for physicians and reg
Externí odkaz:
https://doaj.org/article/d9ac4720e37d456aa3e0668f876f8ecc
Autor:
Natalia Ashtamker, David Ladkani, Masami Tanaka, Hideki Houzen, Toshiro Miura, Takashi Yamamura, Toshiyuki Fukazawa, Volker Knappertz
Publikováno v:
Clinical & Experimental Neuroimmunology
Objective Multiple sclerosis (MS) prevalence, clinical patterns, and treatment responses vary between races and geographical latitudes. Glatiramer acetate (GA; Copaxone) has provided a safe, effective treatment option for relapsing–remitting MS pat
Autor:
Mark Dolev, Zeev Mazor, Yoram Barak, Anat Achiron, Uri Givon, Sigal Liraz Zaltzman, Alon Kalron, Yael Stern, David Ladkani, David Magalashvili
Publikováno v:
Multiple Sclerosis Journal. 21:767-775
Context: Fatigue is one of the most common and disabling symptoms of multiple sclerosis (MS); however, there is no medication that has been approved specifically to treat MS-related fatigue. Objective: We aimed to evaluate the effect of vitamin D ana
Publikováno v:
Journal of the Neurological Sciences. 286:92-98
In a large multicenter randomized, and double blind placebo controlled trial of glatiramer acetate (GA) in primary progressive multiple sclerosis (PPMS), an originally unplanned post hoc analysis suggested that males assigned to GA therapy experience
Autor:
Colin J. D. Ross, Sarah Kolitz, Iris Grossman, Pippa S. Loupe, Ralph Laufer, David Ladkani, Ben Zeskind, Liat Hayardeny, Daphna Laifenfeld, Michael R. Hayden, Volker Knappertz
Publikováno v:
Progress in neurobiology. 152
Multiple sclerosis (MS) is a chronic, progressive, disabling disorder characterized by immune-mediated demyelination, inflammation, and neurodegenerative tissue damage in the central nervous system (CNS), associated with frequent exacerbations and re
Autor:
Arthur Komlosh, Tal Hasson, Shlomo Bakshi, Michael R. Hayden, Kevin D. Fowler, Augusto Grinspan, Tal Birnberg, Maxim N. Artyomov, Liat Hayardeny, Fadi Towfic, Jason M. Funt, Benjamin Zeskind, Rivka Schwartz, Iris Grossman, David Ladkani, Daphna Laifenfeld, Sarah Kolitz
Publikováno v:
Scientific Reports
Glatiramer Acetate (GA) has provided safe and effective treatment for multiple sclerosis (MS) patients for two decades. It acts as an antigen, yet the precise mechanism of action remains to be fully elucidated and no validated pharmacokinetic or phar
Autor:
Galia Shifroni, Marco Rovaris, Giancarlo Comi, David Ladkani, Kenneth P. Johnson, Jerry S. Wolinsky, Aaron E. Miller, Filippo Martinelli Boneschi, Massimo Filippi
Publikováno v:
Multiple Sclerosis Journal. 9:349-355
Three randomized, double-blind, placebo-controlled trials have shown that glatiramer acetate (GA) is effective in reducing relapse rate in patients with relapsing-remitting (RR) multiple sclerosis (MS). Using raw data pooled from 540 patients, we per
Publikováno v:
Journal of Medical Economics. 4:207-219
SUMMARYWe have developed an economic model around the patient level data from the pivotal clinical trial for Copaxone® (glatiramer acetate), combined with published cost and natural history data, to demonstrate cost-effectiveness in relapsing-remitt
Autor:
E. Greinel, I. H. Gomolin, Jerry S. Wolinsky, Suhayl Dhib-Jalbut, David Ladkani, L. R. Rogers, J. Tamulevich, Yafit Stark, B. Gandhi, Staley A. Brod, J. B. Burns, Dennis L. Kolson, Sara G. Austin, K. A. McCarthy, J. W. Rose, S. J. Bird, E. Cerreta, J. H. Parnell, D. Lisak, Kenneth P. Johnson, S. Van Den Noort, L. Smith, L. Pardo, L. W. Myers, J. Guarnaccia, Hillel Panitch, G. W. Ellison, K. L. Conway, Jonathan Goldstein, Christopher T. Bever, C. C. Ford, Andrew D. Goodman, Timothy Vollmer, I. Pinchasi, OA Khan, G. R. Barger, J. W. Lindsey, S. L. Craig, F. J. Vriesendorp, A. Pruitt, B. R. Brooks, M. D. Petri, A. E. Miller, E. Katz, A. McKeon, J. Fleming, C. Kawai, Francisco Gonzalez-Scarano, C. Weasler, W. Mulcahy, A. B. Thomas, S. Reingold, L. P. Weiner, Cris S. Constantinescu, R. P. Lisak, N. Kachuck, D. Pfohl, R. W. Baumhefner, S. Kadosh, M. Dimachkie, D. Mellits
Publikováno v:
Scopus-Elsevier
In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone®) reduced the relapse rate and slowed accumulation of disability for patients with relapsing-remitting multiple sclerosis. Of the original 251 patients randomized
Autor:
Fadi Towfic, Jason M. Funt, Shlomo Bakshi, Rivka Schwartz, David Ladkani, Michael R. Hayden, Benjamin Zeskind, Kevin D. Fowler, Maxim N. Artyomov, Eran Blaugrund
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 1, p e83757 (2014)
PLoS ONE, Vol 9, Iss 1, p e83757 (2014)
For decades, policies regarding generic medicines have sought to provide patients with economical access to safe and effective drugs, while encouraging the development of new therapies. This balance is becoming more challenging for physicians and reg